Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Developments study located that conolidine interacts While using the atypical chemokine receptor ACKR3/